Cytori Therapeutics, Inc. (CYTX)

[Paulness]

NEWS -- Cytori Reports Fourth Quarter and Full Year 2018 Business and Financial Results

• Strategic focus on building a leading oncology company / Lorem Vascular cell therapy transaction yields $4MM
• Letter of intent for ATI-0918 filed with EMEA

SAN DIEGO, April 01, 2019 (GLOBE NEWSWIRE) -- Cytori Therapeutics (CYTX) (“Cytori” or the “Company”) today announced its fourth quarter and year-end 2018 financial results and provided updates on corporate activities. Also announced was a transaction to divest certain cell therapy assets to Lorem Vascular of Melbourne, Australia yielding $4MM in non-dilutive funding to the Company.

Fourth quarter 2018 net loss was $2.2 million, or $0.16 per share. Operating cash burn for the fourth quarter of 2018 was approximately $2.5 million. Cytori ended the year with approximately $5.3 million of cash and cash equivalents.

The Full Press Release can be found here:

https://finance.yahoo.com/news/cytori-reports-fourth-quarter-full-120500623.html